CUMYL-3TMS-PRINACA

Chemical compound

CUMYL-3TMS-PRINACA
Identifiers
  • N-(2-phenylpropan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazole-3-carboxamide
Chemical and physical data
FormulaC23H31N3OSi
Molar mass393.606 g·mol−1
3D model (JSmol)
  • Interactive image
  • C[Si](C)(C)CCCn1nc(C(=O)NC(C)(C)c2ccccc2)c2ccccc12
InChI
  • InChI=1S/C23H31N3OSi/c1-23(2,18-12-7-6-8-13-18)24-22(27)21-19-14-9-10-15-20(19)26(25-21)16-11-17-28(3,4)5/h6-10,12-15H,11,16-17H2,1-5H3,(H,24,27)
  • Key:BFLYAEBVCZMSPK-UHFFFAOYSA-N

CUMYL-3TMS-PRINACA is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. Along with the related compound ADMB-3TMS-PRINACA that was reported several months earlier, CUMYL-3TMS-PRINACA is one of the only psychoactive drugs ever reported that contains a silicon atom.[1] Another example of a silicon-containing drug is sila-haloperidol.[2]

Legality

CUMYL-3TMS-PRINACA is illegal in Germany and Italy and has been recommended for control in Sweden.[3][4]

See also

  • CUMYL-CBMINACA
  • CUMYL-FUBINACA
  • CUMYL-NBMINACA
  • CUMYL-PINACA
  • CUMYL-THPINACA
  • Silandrone

References

  1. ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
  2. ^ "Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate". 2008.
  3. ^ Terp G (26 May 2023). "Yttrande enligt 13 § Lag (2011:111) om förstörande av vissa hälsofarliga missbrukssubstanser" [Opinion according to § 13 Act (2011:111) re destruction of certain health hazards substances of abuse] (PDF). Folkhälsomyndigheten (The Public Health Authority) (in Swedish).
  4. ^ "DECRETO 12 dicembre 2023". Gazzetta Ufficiale (in Italian). 12 December 2023. Update of the tables containing the indication of narcotic and psychotropic substances, pursuant to the decree of the President of the Republic of 9 October 1990, n. 309 and subsequent amendments and additions. Inclusion in Table I of the specific indication of the substances: MDMB-BINACA; N-sec-butyl-pentedrone; CUMIL-3TMS-PRINACA. (23A06995) (GU General Series n.300 of 27-12-2023)
  • v
  • t
  • e
Cannabinoids
Phytocannabinoids
(comparison)
Cannabibutols
  • CBB
Cannabichromenes
Cannabicyclols
  • CBL
    • CBLA
  • CBLB
  • CBLP
    • CBLPA
  • CBLV
    • CBLVA
Cannabidiols
Cannabielsoins
  • CBE
    • CBEA
      • CBEA-A
      • CBEA-B
  • CBEB
  • CBEP
    • CBEPA
  • CBEV
Cannabigerols
  • CBG
    • CBGA
    • CBGB
    • CBGBA
    • CBGM
      • CBGAM
  • CBGP
    • CBGPA
  • CBNR
    • CBNRA
      • CBNRA-A
  • CBGV
    • CBGVA
      • CBGVA-A
  • CBGQ
Cannabiphorols
  • CBP
Cannabinols
  • CBN
    • CBNA
    • CBN-C1
    • CBN-C2
    • CBN-C4
    • CBNM
  • CBND
    • CBNDA
  • CBNP
    • CBNPA
  • CBVD
    • CBVDA
Cannabitriols
  • CBT
    • CBTA
  • CBTB
  • CBTV
    • CBTVA
  • CBTP
    • CBTPA
Cannabivarins
Delta-8-tetrahydrocannabinols
  • Delta-8-THC
    • Delta-8-THCA
      • Delta-8-THCA-A
  • Delta-8-THCB
  • Delta-8-THCP
  • Delta-8-THCV
Delta-9-tetrahydrocannabinols
Delta-10-Tetrahydrocannabinols
Miscellaneous cannabinoids
Active metabolites
EndocannabinoidsSynthetic
cannabinoid
receptor
agonists /
neocannabinoids
Classical cannabinoids
(dibenzopyrans)
Non-classical
cannabinoids
Adamantoylindoles
Benzimidazoles
Benzoylindoles
Cyclohexylphenols
Eicosanoids
Indazole-3-
carboxamides
Indole-3-carboxamides
Indole-3-carboxylates
Naphthoylindazoles
Naphthoylindoles
Naphthoylpyrroles
Naphthylmethylindenes
Naphthylmethylindoles
Phenylacetylindoles
Pyrazolecarboxamides
Tetramethylcyclo-
propanoylindazoles
Tetramethylcyclo-
propanoylindoles
Others
Allosteric CBRTooltip Cannabinoid receptor ligandsEndocannabinoid
enhancers
(inactivation inhibitors)Anticannabinoids
(antagonists/inverse
agonists/antibodies)
  • v
  • t
  • e
Receptor
(ligands)
CB1Tooltip Cannabinoid receptor type 1
Agonists
(abridged,
full list)
Inverse agonists
Antagonists
CB2Tooltip Cannabinoid receptor type 2
Agonists
Antagonists
NAGly
(GPR18)
Agonists
Antagonists
GPR55
Agonists
Antagonists
GPR119
Agonists
Transporter
(modulators)
eCBTsTooltip Endocannabinoid transporter
Enzyme
(modulators)
FAAHTooltip Fatty acid amide hydrolase
MAGL
ABHD6
  • Inhibitors: JZP-169
  • JZP-430
  • KT182
  • KT185
  • KT195
  • KT203
  • LEI-106
  • ML294
  • ML295
  • ML296
  • UCM710
  • WWL-70
ABHD12
Others
  • Others: 2-PG (directly potentiates activity of 2-AG at CB1 receptor)
  • ARN-272 (FAAH-like anandamide transporter inhibitor)
See also
Receptor/signaling modulators
Cannabinoids (cannabinoids by structure)


Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e